|
Titulo |
Therapeutic equivalence of the new oral anticoagulants |
|
Autoría |
Moreno Villar A, Nacle López I, Barbero Hernández MJ, Lizan Tudela L. |
|
Fuente |
Semergen. 2015 Oct;41(7):382-6. doi: 10.1016/j.semerg.2015.04.016. Epub 2015 Jul 3. Spanish. |
|
Resumen |
In an attempt to minimize the economic impact due to the incorporation of innovative drugs, health authorities have promoted and supported the evaluation and market positioning of drugs, as equivalent therapeutic alternatives. This issue has recently gained importance, possibly due to the current economic crisis. The equivalent therapeutic alternatives are justified by the need to compete on price, and by the authorities recommendation to establish therapeutic equivalence, price and financing of medicinal products at the same time. The establishment of the new oral anticoagulants and the equivalent therapeutic alternatives is a problematic issue if it is based on the absence of direct comparisons between different drugs and the questionable methodology used in the current indirect comparisons. Currently, it is difficult to determine when a new oral anticoagulant is more recommendable than others, but efforts are being made in order to propose alternatives for the decision based on patient characteristics. |
|
URL |
www.ncbi.nlm.nih.gov/pubmed/26146035 |
|
Tipo de documento |
Artículo cientifico |
|
Impacto en el sistema sanitario |
-- |
|
Impacto en la salud |
-- |
